Core Faculty


Dr. Yuqing Huo

YUQING HUO, MD, PHD

Professor, Cellular Biology & Anatomy
Director of the Vascular Inflammation Program, Vascular Biology Center

More about Dr. Huo

Contact Info

Phone: (706) 721-4414
Fax: (706) 721-9799
Email: yhuo@augusta.edu
Office: CB-3919A
Lab: CB-3919


Education and Training

Post Doctoral Training
University of Virginia,
Charlottesville, VA.
Cardiovascular Research Center, Department of Biomedical
Engineering.
1998-2001

PhD
Department of Cardiology,
People's Hospital,
Beijing Medical University.
Beijing, P. R. China
1998

MS
Qingdao University,
Qingdao, P. R. China.
Department of Cardiology.
1995

MD
Jining Medical College,
Jining, P. R. China.
1989


Society Memberships

  • American Diabetes Association
  • American Heart Association
  • American Physiological Society

More about Dr. Huo

Research

The research interests of Dr. Huo's laboratory are to study metabolic aspects of human diseases in animal models. These studies include examination of metabolic effect on leukocyte recruitment and activation, fibroblast activation, activation and proliferation of vascular cells in animal models of atherosclerosis, thrombosis, diabetes/obesity, pulmonary hypertension, retinopathy, cardiac hypertrophy and renal fibrosis. The above diseases develop and progress as a result of metabolic modulation in relevant cells. Dr. Huo's laboratory developed in-vitro, ex-vivo, and in-vivo animal models and various engineered mice. Using these animal disease models, epifluoresence intravital microscopy, FCAS and histological approaches as well as various molecular/genetic assays, the phenotypes of disease models are characterized and the underlying molecular mechanisms are studied. Current studies assess the involvement of AMPK, adenosine/adenosine receptors, metabolic molecules such as PFKFB3, ACLY, ACSS2, ATIC and sirtuins in the development and progression of above diseases. These studies are expected to augment basic understanding of metabolic aspect involved in these diseases, and may lead to the development of metabolic therapy for future clinical use in patients.



Highlighted Research News

New treatment target identified for diabetic complications

New pulmonary hypertension treatment target in the bull’s-eye:


Projects

  • The role of adenosine, adenosine receptors and relevant signals in the development of metabolic and inflammatory diseases.
  • The effect of glycolysis and many other metabolic pathways on regulating the functions of leukocytes, fiborblasts and vascular cells as well as the development of various disease.
  • The role of AMPK and related molecules such as ATIC in the development of metabolic and inflammatory diseases.

Lab

Postdoctoral Fellows

Zhiping Liu, Ph.D;

Qiuhua Yang, Ph.D

Visiting Scholars

Jiean Xu

Qian Ma

Xiaoyu Zhang

Xiaoxiao Mao


Recent Publications

More from PubMed

Yuqing Huo Research Google Scholar Citations

Cao Y, Zhang X, Wang L, Yang Q, Ma Q, Xu J, Wang J, Kovacs L, Ayon RJ, Liu Z, Zhang M, Zhou Y, Zeng X, Xu Y, Wang Y, Fulton DJ, Weintraub NL, Lucas R, Dong Z, Yuan JX, Sullivan JC, Meadows L, Barman SA, Wu C, Quan J, Hong M, Su Y, Huo Y. PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension. Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13394-13403. PMID: 31213542; PMCID: PMC6613097.

Zhou Y, Zeng X, Li G, Yang Q, Xu J, Zhang M, Mao X, Cao Y, Wang L, Xu Y, Wang Y, Zhang Y, Xu Z, Wu C, Chen JF, Hoda MN, Liu Z, Hong M, Huo Y. Inactivation of endothelial adenosine A(2A) receptors protects mice from cerebral ischaemia-induced brain injury. Br J Pharmacol. 2019 Jul;176(13):2250-2263. PMID: 30931525; PMCID: PMC6555863.

Kovacs L, Cao Y, Han W, Meadows L, Kovacs-Kasa A, Kondrikov D, Verin AD, Barman SA, Dong Z, Huo Y*, Su Y*. PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019 Feb 28. doi: 10.1164/rccm.201812-2290OC. PMID: 30817168. *Co-corresponding.

Zhang M, Zeng X, Yang Q, Xu J, Liu Z, Zhou Y, Cao Y, Zhang X, An X, Xu Y, Huang L, Han Z, Wang T, Wu C, Fulton DJ, Weintraub NL, Hong M, Huo Y. Ablation of Myeloid ADK (Adenosine Kinase) Epigenetically Suppresses Atherosclerosis in ApoE(-/-) (Apolipoprotein E Deficient) Mice. Arterioscler Thromb Vasc Biol. 2018 Dec;38(12):2780-2792. PMID: 30571174; PMCID: PMC6309817.

Yang Q, Xu J, Ma Q, Liu Z, Sudhahar V, Cao Y, Wang L, Zeng X, Zhou Y, Zhang M, Xu Y, Wang Y, Weintraub NL, Zhang C, Fukai T, Wu C, Huang L, Han Z, Wang T, Fulton DJ, Hong M, Huo Y. PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis. Nat Commun. 2018 Nov 7;9(1):4667. PMID: 30405100; PMCID: PMC6220207.

Xu Y, Wang Y, Yan S, Yang Q, Zhou Y, Zeng X, Liu Z, An X, Toque HA, Dong Z, Jiang X, Fulton DJ, Weintraub NL, Li Q, Bagi Z, Hong M, Boison D, Wu C, Huo Y. Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. Nat Commun. 2017 Oct 16;8(1):943. PMID: 29038540; PMCID: PMC5643397.

Liu Z, Yan S, Wang J, Xu Y, Wang Y, Zhang S, Xu X, Yang Q, Zeng X, Zhou Y, Gu X, Lu S, Fu Z, Fulton DJ, Weintraub NL, Caldwell RB, Zhang W, Wu C, Liu XL, Chen JF, Ahmad A, Kaddour-Djebbar I, Al-Shabrawey M, Li Q, Jiang X, Sun Y, Sodhi A, Smith L, Hong M, Huo Y. Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis. Nat Commun. 2017 Sep 19;8(1):584. PMID: 28928465; PMCID: PMC5605640.

Xu Y, Wang Y, Yan S, Zhou Y, Yang Q, Pan Y, Zeng X, An X, Liu Z, Wang L, Xu J, Cao Y, Fulton DJ, Weintraub NL, Bagi Z, Hoda MN, Wang X, Li Q, Hong M, Jiang X, Boison D, Weber C, Wu C, Huo Y. Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis. EMBO Mol Med. 2017 Sep;9(9):1263-1278. PMID: 28751580; PMCID: PMC5582416.